Invivyd, Inc.

NasdaqGM:IVVD Stock Report

Market Cap: US$61.0m

Invivyd Future Growth

Future criteria checks 5/6

Invivyd is forecast to grow earnings and revenue by 70.3% and 58.4% per annum respectively. EPS is expected to grow by 71.7% per annum. Return on equity is forecast to be -297% in 3 years.

Key information

70.3%

Earnings growth rate

71.7%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate58.4%
Future return on equity-297.0%
Analyst coverage

Low

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Jul 16
Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Mar 29
Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Oct 24
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Jul 04
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Mar 19
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Nov 19
Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Invivyd appoints interim CFO, makes headcount changes

Oct 13

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Sep 12

Adagio Therapeutics GAAP EPS of -$0.47

Aug 15

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Jul 30
We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio names David Hering as permanent CEO and Director

Jul 05

Adagio's Round Trip

Mar 02

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19
We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

Earnings and Revenue Growth Forecasts

NasdaqGM:IVVD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263161461481493
12/31/20251422529284
12/31/202426-186-174-1744
9/30/202412-225-192-192N/A
6/30/20242-204-187-186N/A
3/31/2024N/A-207-182-182N/A
12/31/2023N/A-199-174-173N/A
9/30/2023N/A-170-163-161N/A
6/30/2023N/A-175-184-182N/A
3/31/2023N/A-176-204-202N/A
12/31/2022N/A-241-222-220N/A
9/30/2022N/A-280-246-246N/A
6/30/2022N/A-295-244-244N/A
3/31/2022N/A-289-220-220N/A
12/31/2021N/A-227-185-185N/A
9/30/2021N/A-208-135-135N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IVVD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: IVVD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IVVD is expected to become profitable in the next 3 years.

Revenue vs Market: IVVD's revenue (58.4% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: IVVD's revenue (58.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IVVD is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 11:41
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Invivyd, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Patrick TrucchioH.C. Wainwright & Co.
Michael YeeJefferies LLC